NewsNewsDetails
Analysts are optimistic about leading stocks in the healthcare sector: AbbVie, Agios Pharma, and Resmed receive bullish ratings
Businessinsider
1h ago
Ai Focus
Three analysts have recently expressed bullish views on individual stocks in the healthcare sector. Wells Fargo has maintained a buy rating on AbbVie with a target price of $340; Bank of America Securities has maintained a buy rating on Agios Pharma with a target price of $50; Bank of America Securities has reiterated a buy rating on Resmed with a target price of $320.
Helpful
No.Help

There are several reasons to be optimistic about the healthcare sector. Recently, three analysts have each expressed bullish views on AbbVie (AbbVie, ABBV), Agios Pharma (AGIO), and Resmed (RMD).

AbbVie ( ABBV )

Bank of America analyst Mohit Bansal maintained a 'Buy' rating on AbbVie on October 30th, setting a target price of $340.00. The company's stock closed at $294.89 last Friday.

According to the data from TipRanks.com, Bansal is a five-star analyst with an average return rate of

Currently, analysts have a consistent rating of "strong buy" for AbbVie, with an average target price of $296.55, representing a potential increase of 1.6% from the current level. In a report released on October 30th, TipRanks - DeepSeek also upgraded the stock to "buy" with a target price of $323.00.

Agios Pharma （ AGIO ）

Bank of America securities analyst Alec Stranahan maintained a “buy” rating on Agios Pharma on October 30th, setting a target price of $50.00. The company’s stock closed at $30.55 last Friday, near its 52-week low of $27.14.

According to the data from TipRanks.com, Stranahan is a one-star analyst with an average return rate of

Overall, Wall Street has given Agios Pharma a consistent rating of "Strong Buy" with an average target price of $45.20, which indicates a potential upside of 43.8% from the current level. H.C and Wainwright also began to cover this stock in a report released on October 30th, assigning a "Buy" rating with a target price of $55.00.

Resmed （ RMD ）

Bank of America Securities analyst Lyanne Harrison reiterated today his 'buy' rating on Resmed and set a target price of $320.00. The company's stock closed at $229.94 last Friday.

The average return rate of Harrison is

According to the data from TipRanks.com, Harrison ranks 10,020 out of 12,551 analysts.

Currently, analysts have a consensus rating of "moderate buy" for Resmed, with an average target price of $261.73, representing a potential upside of 6.2% from the current level. In a report released on October 30th, KeyBanc also maintained a "buy" rating for the stock, with a target price of $277.00.

Tip
$0
Like
0
Save
0
Views 29
WalletJYS reminds readers to view blockchain rationally, stay aware of risks, and beware of virtual token issuance and speculation. All content on this site represents market information or related viewpoints only and does not constitute any form of investment advice. If you find sensitive content, please click“Report”，and we will handle it promptly。
Submit
Comment 0
Hot
Latest
No comments yet. Be the first!
Related
Log Scale CEO predicts Bitcoin will reach a new high in 2027
Log Scale Investments CEO Mike Flaum predicts that Bitcoin will reach a new high in 2027 and believes that the four-year cycle has come to an end. Galaxy Research, Fidelity, and Grayscale offer different perspectives from the viewpoints of bottom judgment, recovery signals, and macroeconomic conditions, respectively.
crypto.news
·2026-11-03 03:33:53
21
The Inner Circle recognizes Andrea E and Neal as outstanding professional members.
The Inner Circle recognizes Andrea E and Neal as Pinnacle Professional Member Inner Circle of Excellence, in recognition of her contributions to reading education and literacy development. The article introduces her experience in conducting intensive reading instruction at Einstein Academy in Cocoa, Florida, as well as her work in helping students improve their reading skills through evidence-based literacy interventions.
PR Newswire
·2026-11-03 03:23:31
21
Abu Dhabi ADIPEC opens in 2026; Al-Jaber and Ultraman emphasize energy, AI and investment priorities
ADIPEC 2026 opened in Abu Dhabi, where UAE officials, OpenAI CEO Sam Otman, and other participants discussed energy security, infrastructure investment, artificial intelligence, and international cooperation. Al-Jaber stated that the global energy industry must rethink how to build, protect, and deliver secure energy, while Otman emphasized that sufficient and reliable energy is key to unleashing the next wave of AI innovation and economic growth.
PR Newswire
·2026-11-03 03:04:10
17
Oracle Launches $20 Billion in Equity and Debt Financing to Fund AI Expenditures
Oracle launched $20 billion in equity and debt financing on Monday, including $10 billion in investment-grade bonds and a similar amount of common stock. The funds raised will be used for general corporate purposes, which may include capital expenditures and dividend payments. As the company moves forward with its AI investment and financing plan, investors still have doubts about tech companies' large-scale expenditures.
The Block
·2026-11-03 02:53:56
30
View More
Latest from Author
Refresh
arrow
TSA The new security scanner has a smaller opening, so some luggage may not be able to pass through, but most can still be accommodated.
TSA The new security scanner has a smaller opening, so some luggage may not be able to pass through, but most can still be accommodated.
09-26 23:29   486peopleViews
Micron Technology's stock price fluctuated before its Q4 financial report on September 30; institutions are optimistic about the demand for AI and the increase in storage chip prices.
Micron Technology's stock price fluctuated before its Q4 financial report on September 30; institutions are optimistic about the demand for AI and the increase in storage chip prices.
09-26 21:59   455peopleViews
OpenAI Reveals that AI Proxy Once Accessed Public Data from SEC
OpenAI Reveals that AI Proxy Once Accessed Public Data from SEC
09-26 09:45   478peopleViews
Recommended